相关实验视频
Updated: Sep 15, 2025

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
22.0K
向静血酶:从机械的见解到治疗的边界
Rida Zakar1, Matthew D Neal1, Susan M Shea1,2
1Trauma and Transfusion Medicine Research Center, Department of Surgery.
Current opinion in hematology
|July 15, 2025
概括
酶调节血液凝结和凝块分解对于预防出血和凝血障碍至关重要. 新的生物标志物和向酶疗法为危急疾病提供了改进的诊断和治疗.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 分子生物学分子生物学
背景情况:
- 凝血和纤维素分解是复杂的酶过程,对于血液静止至关重要.
- 关键酶如血栓素,等离子体和ADAMTS13的失调导致血栓和出血性疾病.
- 了解这些酶途径对于管理静血平衡至关重要.
研究的目的:
- 审查凝血和纤维素分解的酶调节.
- 突出酶失调在血栓和出血性疾病中的作用.
- 讨论新兴的诊断生物标志物和治疗策略.
主要方法:
- 在血液静止中酶调节的文献综述.
- 对关键酶的分析,包括血栓素,等离子素和ADAMTS13.
- 检查诊断生物标志物和治疗进展.
主要成果:
- 生物标志物,如血-抗血 (TAT) 和等离子体-α2-抗等离子体 (PAP) 复合物,在危急疾病中具有预后价值.
- 酶生成和活性测定方法的进步正在改善诊断能力.
- 新型疗法,包括XI因子抑制剂和重组ADAMTS13,正在出现.
结论:
- 酶调节的洞察力为凝血障碍提供了新的诊断和治疗方法.
- 将实验室发现转化为临床实践需要进一步的验证.
- 精确的酶疗法在急性护理环境中表现有前途.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
917
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
917
Introduction to Hemostasis
8.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.9K
Extrinsic and Intrinsic Pathways of Hemostasis
9.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.3K
Clot Retraction and Fibrinolysis
6.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
651
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
651
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K

